Glytec, a leader in diabetes management technology, has won the 2025 MedTech Breakthrough Award for "Best Computerized Decision Support Solution" for its flagship Glucommander software. This FDA-cleared, cloud-based platform is designed to improve insulin dosing accuracy in hospitals by using both real-time and historical patient data. Glucommander personalizes insulin therapy by learning from each patient's insulin sensitivity and metabolic response, reducing the risk of human error and improving safety and clinical outcomes. With over 100 supporting patents and publications, the software is widely recognized as a transformative tool in glycemic management.

The award highlights the growing need for intelligent clinical decision support in healthcare, particularly as diabetes and blood glucose complications affect 30–50% of hospitalized patients. By automating insulin calculations and integrating seamlessly with hospital systems, Glucommander not only improves patient care but also enhances workflow efficiency for clinicians. The platform's ability to continuously learn and adapt helps care teams respond more effectively to changing patient needs, aligning with new CMS quality measures for hypo- and hyperglycemia management.

This recognition by MedTech Breakthrough underscores Glytec's impact in advancing digital health innovation. Competing against a record number of entries from over 18 countries, the award affirms Glytec’s role in setting new standards for diabetes care in hospital settings. As healthcare systems face rising demand for better chronic disease management, solutions like Glucommander demonstrate how advanced technology can drive both clinical excellence and operational sustainability.